References
- Sawada T, Shikata T, Matsumara T. Analysis of 598 cases of neuroblastoma (NB) detected by screening and changes in the age distribution and incidence of NB patients after mass screening in infants in Japan. Prog Clin Biol Res. 1994; 385: 371–375
- Nishi M, Miyake H, Takeda T. Cases of spontaneous regression and true patients detected in mass screening for neuroblastoma. Int J Pediatr Hematol Oncol. 1995; 1: 557–563
- Ollert M W, David K, Schmitt C. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci USA. 1996; 93: 4498–4503
- Ollert M W, Kadlec J V, David K. Antibody-mediated complement activation on nucleated cells: a quantitative analysis of the individual reaction steps. J Immunol. 1994; 153: 2213–2221
- Beck D, De Bernardi B, Michon J. Phase II clinical trial of surgery as the only treatment for INSS stage 2 neuroblastoma (94.01 trial and study of the localized neuroblastoma European study group; SIOP 95–01 Study). Med Pediatr Oncol. 1995; 25: 278
- David K, Ollert M W, Juhl H. Growth arrest of large solid human neuroblastoma xenografts in nude rats by natural IgM from healthy humans. Proc Am Assoc Cancer Res. 1996; 37: 487